↓ Skip to main content

GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma

Overview of attention for article published in Medical Oncology, September 2011
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

1 research highlight platform


29 Dimensions

Readers on

13 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma
Published in
Medical Oncology, September 2011
DOI 10.1007/s12032-011-0070-2
Pubmed ID

Jean-Philippe Spano, Y. Vano, S. Vignot, T. De La Motte Rouge, L. Hassani, R. Mouawad, F. Menegaux, D. Khayat, L. Leenhardt


Treatment options for radioiodine resistant metastatic thyroid cancer patients are limited, and chemotherapy is considered an outdated therapeutic method for differentiated thyroid carcinoma. In this study, we evaluated the activity and safety of gemcitabine and oxaliplatin combination which is considered an out of label therapeutic method in patients with differentiated metastatic thyroid cancer refractory to 131-I treatment. Fourteen refractory patients (8 papillary, 6 follicular), six men/eight women with median age of 63 years and performance status (0-3) were included. Patients received gemcitabine (1,000 mg/m(2)) plus oxaliplatin (100 mg/m(2)) every 2 weeks until 12-cycles and each cycle correspond to 2 weeks treatment. This protocol was approved by the local Institutional Review Boards. Response rate was assessed every four cycles. Progression-free and overall survivals were calculated. Median treatment was 9.5 cycles (range 2-17) with 22 weeks duration. Overall response rate was 57%, with 7% achieving a complete response (1/14), 50% a partial response (7/14), and 28% with a stable disease. All patients with follicular subtype showed objective responses. Eleven patients progressed at a median time of 10.1 months; 10 of 14 patients still alive and the median survival was not reached (median follow-up of 19.8 months). The combination was generally well tolerated. No deaths occurred due to therapy and no grade IV toxicity was recorded. The most common treatment-related adverse events grade 1/3 includes asthenia, peripheral neuropathy, diarrhea, anemia, thrombocytopenia, and neutropenia. In conclusion, the GEMOX regimen is well tolerated and effective in advanced differentiated thyroid cancer. However, this retrospective data on a small sample size are considered preliminary and needs to be evaluated prospectively in a higher number of patients in a clinical trial.

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 8%
Brazil 1 8%
Unknown 11 85%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 23%
Other 2 15%
Student > Master 2 15%
Student > Bachelor 1 8%
Professor > Associate Professor 1 8%
Other 1 8%
Unknown 3 23%
Readers by discipline Count As %
Medicine and Dentistry 8 62%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Unknown 4 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 January 2015.
All research outputs
of 13,025,266 outputs
Outputs from Medical Oncology
of 754 outputs
Outputs of similar age
of 275,171 outputs
Outputs of similar age from Medical Oncology
of 51 outputs
Altmetric has tracked 13,025,266 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 754 research outputs from this source. They receive a mean Attention Score of 2.7. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,171 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.